Biogen (BIIB) Common Equity (2009 - 2026)

Biogen (BIIB) has reported Common Equity for 18 consecutive years, with $18.7 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity rose 9.85% year-over-year to $18.7 billion; the TTM figure through Mar 2026 stood at $18.7 billion (up 9.85% YoY), while the FY2025 annual figure was $18.3 billion, up 9.22% from the prior year.
• Common Equity came in at $18.7 billion for Q1 2026 at Biogen, up from $18.3 billion in the prior quarter.
• The five-year high for Common Equity was $18.7 billion in Q1 2026, with the low at -$171.2 million in Q3 2025.
• Average Common Equity over 5 years is $14.3 billion, with a median of $14.8 billion recorded in 2023.
• Across the five-year window, Common Equity rose 22.87% in 2023 and plunged 101.05% in 2025, its largest moves.
• Year by year, Common Equity stood at $13.4 billion in 2022, then advanced by 10.54% to $14.8 billion in 2023, then gained by 12.95% to $16.7 billion in 2024, then climbed by 9.22% to $18.3 billion in 2025, then grew by 2.16% to $18.7 billion in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $18.7 billion, $18.3 billion, and -$171.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.